Market closedNon-fractional
Viridian Therapeutics/VRDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Ticker
VRDN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
94
Website
www.viridiantherapeutics.com
VRDN Metrics
BasicAdvanced
$1B
Market cap
-
P/E ratio
-$4.41
EPS
1.17
Beta
-
Dividend rate
Price and volume
Market cap
$1B
Beta
1.17
Financial strength
Current ratio
23.991
Quick ratio
23.473
Long term debt to equity
3.643
Total debt to equity
3.769
Interest coverage (TTM)
-104.84%
Management effectiveness
Return on assets (TTM)
-29.24%
Return on equity (TTM)
-46.75%
Valuation
Price to revenue (TTM)
2,807.078
Price to book
2.72
Price to tangible book (TTM)
2.72
Price to free cash flow (TTM)
-4.806
Growth
Revenue change (TTM)
-82.59%
Earnings per share change (TTM)
-7.59%
3-year revenue growth (CAGR)
-44.37%
3-year earnings per share growth (CAGR)
-45.76%
What the Analysts think about VRDN
Analyst Ratings
Majority rating from 15 analysts.
VRDN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$49M
-27.40%
Profit margin
0.00%
NaN%
VRDN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.27
-$1.09
-$1.35
-$0.79
-
Expected
-$1.29
-$1.27
-$1.00
-$1.10
-$0.90
Surprise
-1.89%
-13.91%
34.59%
-28.43%
-
VRDN News
AllArticlesVideos
Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
Seeking Alpha·1 month ago
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
Business Wire·1 month ago
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viridian Therapeutics stock?
Viridian Therapeutics (VRDN) has a market cap of $1B as of July 26, 2024.
What is the P/E ratio for Viridian Therapeutics stock?
The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of July 26, 2024.
Does Viridian Therapeutics stock pay dividends?
No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Viridian Therapeutics dividend payment date?
Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Viridian Therapeutics?
Viridian Therapeutics (VRDN) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Viridian Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.